Acetaminophen Reagents Market Overview, Future Trends and Forecast...

Acetaminophen Reagents Market Overview, Future Trends and Forecast

Posted 2022-09-22 12:28:34

189

Acetaminophen is a p-aminophenol derivative that functions as an analgesic and antipyretic. Acetaminophen (paracetamol) is the commonly used analgesic globally. Acetaminophen reagents are particular drug testing reagents that are used to determine the presence of an excessive amount of Acetaminophen in a blood sample. Acetaminophen reagents are also used to assess drug levels and are an essential metric in the treatment and dose management of patients with severe renal failure.

Market leaders operating in the market have undertaken various organic growth strategies in the acetaminophen reagents market. The acetaminophen reagents market majorly consists of the players MD Biorbyt Ltd., Thermo Fisher Scientific Inc., Siemens Healthineers AG, Abbott, Sekisui Diagnostics, Beckman Coulter, Inc., Randox Laboratories, Ltd., American Screening Corporation, Inc., EKF Diagnostics, Bio-Rad Laboratories Inc. among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaboration.

Below is the list of the growth strategies done by the players operating in the Acetaminophen reagents market:

Company	Month & Year	Category	Description
Thermo Fisher Scientific	Nov-2021	Company News	As assay developers and clinical testing laboratories consider next steps for molecular diagnostics post-pandemic, a new in vitro diagnostic (IVD) system from Thermo Fisher Scientific will enable them to expand their assay menus and IVD testing capabilities moving forward.
Thermo Fisher Scientific	Sep-2021	Company News	Thermo Fisher Scientific Inc. has announced plans to establish a manufacturing facility in Nashville dedicated to the production of single-use technologies (SUT) products. This investment is in addition to the previously announced expansion to address unprecedented demand in the bioprocessing market. The facility will be one of the world's largest SUT manufacturing sites and will more than double the company's SUT manufacturing capacity in support of its biopharma customers. The first phase of construction will be operational by the second quarter of 2022.
Siemens Healthiness	Sep-2021	Expansion	The company plans to grow its current location in Building 100 of Glasgow Business Community by 29,000 square feet to add more capacity to manufacture up to 20 new in vitro diagnostic assays, along with associated calibrator products.
Sekisui Diagnostics	Nov-2021	Company News	SEKISUI Diagnostics announces it has received CE Marking for the OSOM Ultra Plus Flu A&B Test and has begun marketing in Europe. The test utilizes traditional lateral flow technology with performance near or exceeding sensitivity of other reader-based tests without using an instrument.
Sekisui Diagnostics	Jul-2020	Expansion	Sekisui announces the decision to invest £14.4 Million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent to be completed by the second half of 2022. This investment follows the investment of $1.9 million in its new Bioprocess Innovation Centre, completed in October 2019, and is part of a long-term investment strategy to grow its share of the microbial biopharma CDMO market.
Sekisui Diagnostics	Oct-2019	Company News	Sekisui Diagnostics' Enzyme business completed a new BioProcess Innovation Centre at its site in Maidstone, Kent by the end of 2019, following a US$1.9 million investment. This investment is part of a long-term investment strategy to grow its share of the microbial biopharma CDMO market, with future investment expected to focus on expanding cGMP manufacturing capabilities.
Beckman Coulter Inc.	Oct-2021	Expansion	Building on a relentless commitment to customer service and innovation, Beckman Coulter Life Sciences debuts a powerful new interactive customer resource with the launch of its Digital Campus. The 3D platform provides greater access to the company’s resources regardless of physical location and allows users to control their experience including the chance to get up close and personal with products and experts from the comfort of their own space and pace.
Thermo Fisher Scientific	Jul-2021	Mergers and Acquisitions	Thermo Fisher Scientific Inc., the world leader in serving science, announced that it has completed its acquisition of PPD, Inc., a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.
Siemens Healthineers	Feb-2021	Collaboration	Thermo Fisher Scientific, the world leader in serving science, has announced a collaboration with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analysers.
Beckman Coulter Inc.	Oct-2018	Company News	Siemens Healthineers and Sysmex Corporation announced the renewal of the companies' long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis products including a multi-year extension.
Randox Health	Jul-2021	Collaboration	Beckman Coulter Diagnostics, a global leader in the clinical diagnostics industry, has embarked on a strategic collaboration with the University of California, Irvine – one of the first targeted academic partnerships the company envisions around the globe.
Acquisition of Advanced Diagnostic Laboratory LLC	Nov-2021	Partnership	Randox Health, the UK’s largest Covid-19 PCR testing provider, partnership with Roadchef Motorway Services, to expand its Covid-19 test kit dropbox network by an additional 20 sites across the UK.
Bio-Rad Laboratories, Inc.	Jul-2021	Mergers and Acquisitions	EKF Diagnostics Holdings plc, the AIM-listed point-of-care business, announces that it has agreed to acquire, pursuant to the terms of a securities purchase agreement dated 27 September 2021, the entire issued capital of Advanced Diagnostic Laboratory LLC, a Texas based PCR-focused testing laboratory certified under the Clinical Laboratory Improvement Amendments (“CLIA”) for high complexity testing, for an initial consideration payment of $10 million payable in shares on completion, with further performance-based consideration payable over the following three years as detailed below (the “Acquisition”).
Bio-Rad Laboratories, Inc.	Apr-2020	Partnership	Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products.
Thermo Fisher Scientific	Jul-2021	Mergers and Acquisitions	Bio-Rad Laboratories, Inc. has acquired Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cells. Terms of the acquisition were not disclosed.

Please log in to like, share and comment!